Cell Biotech Obtains US Patent for CBT Probiotic Drug Delivery System

[Asia Economy Reporter Lee Gwan-joo] Cell Biotech announced on the 20th that its patented strain of kimchi lactic acid bacteria, 'CBT-SL4,' has obtained a U.S. patent related to a lactic acid bacteria drug delivery system.

Cell Biotech explained that through this patent, it has demonstrated the excellence and advancement of the lactic acid bacteria drug delivery system (DDS) that safely delivers therapeutic drugs to the intestines for expression and secretion.

DDS functions like a cassette, allowing versatile applications by simply changing the specific DNA (tape) to be carried. This enables broad applications in various fields such as biotechnology and therapeutic protein pharmaceuticals. The system is developed as an oral drug, enhancing ease of administration, improving side effects and economic burdens of existing treatments, thereby increasing safety and efficiency. Since it delivers drugs directly to the intestines, higher therapeutic efficacy is expected.

Furthermore, for the kimchi lactic acid bacteria CBT-SL4 to perform the DDS role, 'DNA recombination technology,' considered a core technology of lactic acid bacteria-based gene therapy, and the 'expression vector production core technology,' known as the DNA carrier, are required. Cell Biotech has secured these technologies through related patents and plans to expand new drug development into various research pipelines such as diabetes treatments and gastric cancer therapies by utilizing them.

Ryu Yong-gu, Deputy Director of Cell Biotech's Microbiome Research Institute, said, "Based on 28 years of research and technology, Cell Biotech is developing 'PP-P8,' an innovative colorectal cancer drug based on the Korean microbiome," adding, "We will become a leading Korean company in microbiome drug development, based on the proven safety of CBT lactic acid bacteria, which is different from conventional synthetic compound anticancer drugs."

This content was produced with the assistance of AI translation services.